Recurrent Non-small Cell Lung Cancer Completed Phase 1 / 2 Trials for Bevacizumab (DB00112)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00101348Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerTreatment